Gilead Sciences (NASDAQ:GILD) received a $94.00 price objective from research analysts at Maxim Group in a research report issued on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target would suggest a potential upside of 23.88% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. BMO Capital Markets restated a “hold” rating and issued a $82.00 price target on shares of Gilead Sciences in a report on Friday, October 20th. J P Morgan Chase & Co set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. Vetr upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price target for the company in a report on Wednesday, September 6th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $83.00 price target (up from $77.00) on shares of Gilead Sciences in a report on Friday, October 6th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $85.11.

Gilead Sciences (NASDAQ GILD) traded up $1.66 on Monday, hitting $75.88. 9,162,583 shares of the stock traded hands, compared to its average volume of 9,197,427. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $86.27. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The firm has a market capitalization of $99,410.00, a PE ratio of 7.75, a PEG ratio of -1.24 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same period in the prior year, the company posted $2.75 earnings per share. Gilead Sciences’s revenue for the quarter was down 13.2% compared to the same quarter last year. equities research analysts anticipate that Gilead Sciences will post 8.53 EPS for the current fiscal year.

In other news, EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.65, for a total transaction of $2,066,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders have sold 494,999 shares of company stock valued at $37,404,139 over the last quarter. Corporate insiders own 1.30% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Seizert Capital Partners LLC lifted its position in shares of Gilead Sciences by 4.6% during the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after purchasing an additional 27,547 shares in the last quarter. Investment Centers of America Inc. raised its position in Gilead Sciences by 7.2% in the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock worth $1,979,000 after acquiring an additional 1,958 shares during the period. Fagan Associates Inc. raised its position in Gilead Sciences by 2.6% in the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock worth $2,341,000 after acquiring an additional 845 shares during the period. Dai Ichi Life Insurance Company Ltd raised its position in Gilead Sciences by 7.6% in the second quarter. Dai Ichi Life Insurance Company Ltd now owns 160,025 shares of the biopharmaceutical company’s stock worth $11,327,000 after acquiring an additional 11,299 shares during the period. Finally, Capital Asset Advisory Services LLC bought a new stake in Gilead Sciences in the second quarter worth about $875,000. 76.23% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/12/11/gilead-sciences-gild-pt-set-at-94-00-by-maxim-group.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.